You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

Citation Tools

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vergote I, Randall L, Kalbacher E, et al
EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
International Journal of Gynecologic Cancer 2021;31:A129-A130.